Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3PRNewsWire • 02/14/23
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug DevelopmentBusiness Wire • 02/13/23
Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/09/23
AstraZeneca Stock Jumps As Upbeat Guidance Offsets Mixed Quarterly ReportInvestors Business Daily • 02/09/23
As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023CNBC • 02/09/23
AstraZeneca PLC modestly undershoots consensus in the fourth quarter; targeting low double digit sales growth this yearProactive Investors • 02/09/23
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)Benzinga • 02/03/23
TEZSPIRE® approved for self-administration in the US with a new pre-filled penBusiness Wire • 02/02/23
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/30/23